$RTSN SEC Filings

Filed On	Filing
23 Oct 2026	8-K: Departure/Election of Directors or Officers; Compensation On October 21, 2026, the Board of Directors of Retension Pharmaceuticals, Inc. (the “Company” or “Retension”) appointed Robert Wong as Vice President, Chief Accounting Officer (Principal Accounting Officer) of the Company, effective as o...
22 Oct 2026	Form 4: Keller Eric L., Director Granted 40,884 Stock Option (right to buy)
16 Oct 2026	Form 3: B Group, Inc., 10% owner Holds 833,333 shares of Common Stock
16 Oct 2026	SCHEDULE 13G
16 Oct 2026	SCHEDULE 13G
15 Oct 2026	SCHEDULE 13G
14 Oct 2026	SCHEDULE 13D
13 Oct 2026	REGISTRATION STATEMENT
13 Oct 2026	Form 4: Keller Eric L., Director Bought 20,800 shares ($250K) · Received 41,030 shares by conversion · Granted 255,174 Stock Option (right to buy)
13 Oct 2026	Form 4: Sweetnam Paul, CHIEF SCIENTIFIC OFFICER Received 6,666 shares by conversion
13 Oct 2026	Form 4: Olds Donald, Director Received 5,637 shares by conversion
13 Oct 2026	Form 4: Cheruvu Pavan, Director Granted 5,636 Stock Option (right to buy)
13 Oct 2026	Form 4: Bisson Sabine, CHIEF OPERATING OFFICER Received 4,115 shares by conversion
13 Oct 2026	Form 4: Berger Franklin M, Director Received 12,517 shares by conversion · Bought 10,000 shares ($120K)
13 Oct 2026	Form 4: Berendt Michael J, Director Received 6,666 shares by conversion
13 Oct 2026	Form 3: Cheruvu Pavan, Director No securities owned
13 Oct 2026	8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year The address of the registered office of Retension Pharmaceuticals, Inc. (the “Corporation”) in the State of Delaware, and the name of its registered agent at such address, shall be as set forth in the Corporation’s certificate of incorpo...
09 Oct 2026	PROSPECTUS
08 Oct 2026	Form 4: Berendt Michael J, Director Granted 5,636 Stock Option (right to buy)
08 Oct 2026	Form 4: Olds Donald, Director Granted 5,636 Stock Option (right to buy)

Comments